Fortis Therapeutics

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, focusing on the development of antibody-drug conjugate therapies targeting CD46 proteins. These therapies are designed for the treatment of late-stage multiple myeloma and prostate cancer, among other indications. The company operates within the Community of Innovation in San Diego, leveraging cutting-edge science and technology to advance cancer treatment. Fortis Therapeutics' business model revolves around the research and development of precision therapies that selectively target tumor cells while sparing normal tissues, thereby enhancing treatment efficacy and safety. The company generates revenue through the development and potential commercialization of its proprietary therapies. Fortis serves the healthcare sector, specifically targeting patients with advanced cancer stages who require innovative treatment options. The company's approach is grounded in the understanding that CD46 is upregulated in tumor cells, making it an ideal target for antibody-drug conjugates. By focusing on this specific protein, Fortis aims to improve outcomes for patients with resistant forms of cancer. Keywords: immuno-oncology, biotechnology, antibody-drug conjugates, CD46 proteins, cancer treatment, multiple myeloma, prostate cancer, precision therapies, tumor targeting, healthcare.